Pyridam Farma Tbk PT
IDX:PYFA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
89
1 400
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pyridam Farma Tbk PT
Pyridam Farma Tbk PT
Other Current Liabilities
Pyridam Farma Tbk PT
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Other Current Liabilities
Rp117.9B
|
CAGR 3-Years
49%
|
CAGR 5-Years
101%
|
CAGR 10-Years
42%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Other Current Liabilities
Rp499.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
29%
|
CAGR 10-Years
12%
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Other Current Liabilities
Rp954.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Other Current Liabilities
Rp83.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
20%
|
CAGR 10-Years
28%
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Other Current Liabilities
Rp94.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Other Current Liabilities
Rp342.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
Pyridam Farma Tbk PT
Glance View
PT Pyridam Farma Tbk engages in the production and development of pharmaceutical medicines, and trading of medical supplies. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,539 full-time employees. The company went IPO on 2001-10-16. The firm operates through two segments: Pharmaceutical Products and Toll Manufacturing Services, and Medical Device Products. Its business consists of production and/or distribution of modern and traditional medicines and distribution of medical devices, such as laboratory equipment and PCR test kits. The company offers products across consumer health, prescription, pyfaesthetic and biomedilab categories. The company produces various kinds of pharmaceuticals products ranging from antibiotics, vitamins and health supplements. The firm offers its products in the form of effervescent tablets, capsules, caplets, syrups and creams. Its prescription production has several properties, such as anti-infection, anti-inflammatory, anti-parkinsonian, anti-epileptic, and other indications. The company provides toll manufacturing services to produce products owned by the Company’s partner companies in accordance with predetermined specifications.
See Also
What is Pyridam Farma Tbk PT's Other Current Liabilities?
Other Current Liabilities
117.9B
IDR
Based on the financial report for Sep 30, 2024, Pyridam Farma Tbk PT's Other Current Liabilities amounts to 117.9B IDR.
What is Pyridam Farma Tbk PT's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
42%
Over the last year, the Other Current Liabilities growth was 397%. The average annual Other Current Liabilities growth rates for Pyridam Farma Tbk PT have been 49% over the past three years , 101% over the past five years , and 42% over the past ten years .
You don't have any saved screeners yet
